US Pharma MarketingFDA to hold adcomm for Grail cancer test that failed in large, randomized trial
The FDA will host an advisory committee meeting in September to review Grail's controversial cancer test that failed to meet the primary endpoint of a large, randomized trial in the UK. Grail’s early cancer detection ...
The FDA will host an advisory committee meeting in September to review Grail's controversial cancer test that failed to meet the primary endpoint of a large, randomized trial in the UK.
Grail’s early cancer detection ...
Source: Endpoints News